Compare · CRDF vs KURA
CRDF vs KURA
Side-by-side comparison of Cardiff Oncology Inc. (CRDF) and Kura Oncology Inc. (KURA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CRDF focuses on Biotechnology: Biological Products (No Diagnostic Substances), while KURA focuses on Biotechnology: Pharmaceutical Preparations.
- KURA is the larger of the two at $1.21B, about 15.2x CRDF ($79.4M).
- Over the past year, CRDF is down 53.8% and KURA is up 78.9% - KURA leads by 132.8 points.
- KURA has been more active in the news (10 items in the past 4 weeks vs 4 for CRDF).
- KURA has more recent analyst coverage (18 ratings vs 14 for CRDF).
- Company
- Cardiff Oncology Inc.
- Kura Oncology Inc.
- Price
- $1.02+2.53%
- $13.58+9.52%
- Market cap
- $79.4M
- $1.21B
- 1M return
- +21.88%
- +33.79%
- 1Y return
- -53.85%
- +78.92%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 4
- 10
- Recent ratings
- 14
- 18
Cardiff Oncology Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Kura Oncology Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Latest CRDF
- Cardiff Oncology downgraded by William Blair
- Cardiff Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
- SEC Form 10-Q filed by Cardiff Oncology Inc.
- SEC Form S-8 filed by Cardiff Oncology Inc.
- Director Pace Gary W bought $1,000,000 worth of shares (687,285 units at $1.46), increasing direct ownership by 51% to 2,043,661 units (SEC Form 4)
- Chief Executive Officer Mohindru Mani bought $50,000 worth of shares (34,364 units at $1.46), increasing direct ownership by 139% to 59,067 units (SEC Form 4)
- Cardiff Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Cardiff Oncology Inc.
- Cardiff Oncology Announces $10 Million Registered Direct Offering
Latest KURA
- Chief Commercial Officer Powl Brian T. sold $51,663 worth of shares (4,345 units at $11.89) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 169,269 units (SEC Form 4)
- President and CEO Wilson Troy Edward bought $1,239,000 worth of shares (100,000 units at $12.39) (SEC Form 4)
- Chief Legal Officer Bair Teresa Brophy sold $397,681 worth of shares (31,487 units at $12.63) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 195,444 units (SEC Form 4)
- President and CEO Wilson Troy Edward bought $1,112,000 worth of shares (100,000 units at $11.12) (SEC Form 4)
- SEC Form 10-Q filed by Kura Oncology Inc.
- Kura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kura Oncology Reports Second Quarter 2026 Financial Results
- Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Kura Oncology to Report Second Quarter Financial Results